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ABSTRACT
Background
A pandemic H5N1 influenza outbreak would be facilitated by an absence of immunity to the
avian-derived virus in the human population. Although this condition is likely in regard to
hemagglutinin-mediated immunity, the neuraminidase (NA) of H5N1 viruses (avN1) and of
endemic human H1N1 viruses (huN1) are classified in the same serotype. We hypothesized that
an immune response to huN1 could mediate cross-protection against H5N1 influenza virus
infection.
Methods and Findings
Mice were immunized against the NA of a contemporary human H1N1 strain by DNA
vaccination. They were challenged with recombinant A/Puerto Rico/8/34 (PR8) viruses bearing
huN1 (PR8-huN1) or avN1 (PR8-avN1) or with H5N1 virus A/Vietnam/1203/04. Additional naı ¨ve
mice were injected with sera from vaccinated mice prior to H5N1 challenge. Also, serum
specimens from humans were analyzed for reactivity with avN1. Immunization elicited a serum
IgG response to huN1 and robust protection against the homologous challenge virus.
Immunized mice were partially protected from lethal challenge with H5N1 virus or recombinant
PR8-avN1. Sera transferred from immunized mice to naı ¨ve animals conferred similar protection
against H5N1 mortality. Analysis of human sera showed that antibodies able to inhibit the
sialidase activity of avN1 exist in some individuals.
Conclusions
These data reveal that humoral immunity elicited by huN1 can partially protect against H5N1
infection in a mammalian host. Our results suggest that a portion of the human population
could have some degree of resistance to H5N1 influenza, with the possibility that this could be
induced or enhanced through immunization with seasonal influenza vaccines.
The Editors’ Summary of this article follows the references.
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The ongoing spread of highly pathogenic avian H5N1
inﬂuenza virus across Eurasia and Africa has led to over 200
conﬁrmed infections in humans, more than half of whom
have died [1]. In the event that an H5N1 strain gains the
ability to spread efﬁciently from human to human, the lack of
subtype-speciﬁc immunity would make the human popula-
tion highly vulnerable. Indeed, the occurrence of pandemic
inﬂuenza relies on a lack of immunity to the virus in a large
proportion of the human population.
Currently licensed seasonal inﬂuenza vaccines are designed
to protect humans from the prevailing strains of human
inﬂuenza A lineages H1N1 and H3N2 and of inﬂuenza B
virus. These vaccines’ principal target is the most abundant
viral surface antigen, hemagglutinin (HA). Immunization
against this sialic acid receptor–binding glycoprotein typi-
cally elicits neutralizing antibodies, which may act by block-
ing the attachment of the virus to host-cell receptors or by
interfering with HA-mediated viral fusion [2,3]. The annually
determined trivalent inﬂuenza vaccines are standardized on
the basis of the content of their HA components. Neurami-
nidase (NA), the other major surface protein and determinant
of serotype, is not standardized in current vaccines, meaning
that the amount is likely to vary from batch to batch.
Antibodies against NA do not block infection, but they can
inhibit the enzymatic activity of NA [4,5]. Therefore,
immunization against NA can decrease viral replication in
the lungs and reduce disease severity upon subsequent
challenge [4–7]. Although HA and NA are both highly
immunogenic, intact inﬂuenza virions reportedly induce a
humoral response skewed toward HA because of antigenic
competition [8]. However, immunization with a commercial
trivalent subvirion vaccine in which the HA and NA
components are dissociated increases NA-speciﬁc antibody
titers in humans [9].
Although the NA of avian H5N1 inﬂuenza virus strains
(avN1) and of human H1N1 strains (huN1) are classiﬁed in the
same serotype, phylogenetic differences between the two
lineages are considerably greater than those within each
lineage. Despite clear public health implications, it remains
unknown whether antibodies raised against huN1 can inhibit
replication of H5N1 inﬂuenza virus or mediate any degree of
protection from H5N1 infection. Standard trivalent human
inﬂuenza vaccines regularly require substitution of the H1N1
component to optimize protection against new prevailing
strains. This fact suggests that cross-lineage protective
immunity is improbable, particularly in the case of H1N1
versus H5N1, of which HA genes have low homology. Still,
even limited cross-reactivity between H5N1 virus and pre-
existing huN1-speciﬁc antibodies or T cells might reduce viral
replication and disease, with signiﬁcant implications for
H5N1 infection in the human population.
Methods
Viruses and Vaccine
A/Hong Kong/213/03 (H5N1) and A/Vietnam/1203/04
(H5N1) inﬂuenza viruses were obtained from the World
Health Organization collaborating laboratories. A/New Cale-
donia/20/99 (H1N1) inﬂuenza virus was obtained from the
virus repository of Dr. Robert Webster (St. Jude Children’s
Research Hospital, Memphis, Tennessee, United States). Gene
segments of A/Vietnam/1203/04, A/New Caledonia/20/99, and
A/Puerto Rico/8/34 (PR8) (H1N1) inﬂuenza viruses were
cloned into plasmids for virus rescue and gene reassortment
by the 8-plasmid reverse genetics method, as described
previously [10,11]. Viruses so derived were propagated in
the allantoic cavities of 10-d-old embryonated chickens’ eggs.
These reassortant viruses include ‘‘PR8-huN1,’’ which bears
the NA gene segment of human-lineage A/New Caledonia/20/
99 and seven complementary gene segments of PR8, and
‘‘PR8-avN1,’’ which bears the NA gene segment of avian-
lineage A/Vietnam/1203/04 and seven complementary gene
segments of PR8. A DNA vaccine was constructed by cloning
the nucleotide sequence of the open reading frame of the NA
gene segment of A/New Caledonia/20/99 (huN1) into the
plasmid backbone VR10551. Expression of this sequence was
under the control of a human cytomegalovirus promoter [12].
Animals and Experimental Design
BALB/cJ mice were purchased from The Jackson Labora-
tory (http://www.jax.org) and housed in the Animal Resources
Center at St. Jude Children’s Research Hospital. Mice (aged 7
wk) received intramuscular injections of huN1 DNA vaccine
(100 lg), control diluent, or plasmid lacking a gene insert (100
lg) at weeks 0 and 3. Serum was collected from orbital bleeds
taken before secondary vaccination and before viral chal-
lenge. At week 6, under Animal Biosafety Level 3 enhanced
conditions, mice were anesthetized with avertin and inocu-
lated intranasally with challenge viruses. PR8-huN1, PR8-
avN1, and A/Vietnam/1203/04 were administered at doses of
10 and 100 50% MLD50 (mouse lethal doses). Body weights
were monitored regularly and deaths noted daily. Individual
animals showing obvious hind limb paralysis were euthanized
humanely. To achieve passive immunization, 11-wk-old
BALB/cJ mice were intraperitoneally injected with 350 llo f
serum collected from above-mentioned mice as follows.
HuN1-immune serum was pooled from huN1 DNA-vacci-
nated mice 17–20 d after administration of dose 2. Positive
control serum was pooled from mice that survived challenge
with A/Vietnam/1203/04 (H5N1) virus, and negative control
serum was pooled from saline-injected mice. Recipient mice
were challenged with 10 MLD50 of A/Vietnam/1203/04 18 h
after passive immunization.
Serology
Sera from huN1-immunizedm i c ew e r et r e a t e dw i t h
receptor-destroying enzyme and analyzed by ELISA for
speciﬁcity to PR8-huN1 and PR8-avN1 viral antigens. These
viral antigens were propagated in 10-d-old embryonated
chickens’ eggs, concentrated, puriﬁed over sucrose gradients,
and pelleted by ultracentrifugation. Microtiter plates were
coated with PR8-huN1or PR8-avN1 (6 lg/ml in suspension) by
overnight incubation at 4 8C. After plates were washed six
times with PBS containing 0.05% Tween 20 (PBS-Tween) and
nonspeciﬁc antibody binding was blocked by incubation for 2
h with PBS-Tween with 10% fetal bovine serum; sera were
added in a series of doubling dilutions. Overnight incubation
at 4 8C was followed by washing with PBS-Tween, incubation
with alkaline phosphatase-conjugated goat anti-mouse IgG
(Southern Biotech [http://www.southernbiotech.com]) for 2 h
at room temperature, further washing with PBS-Tween, and
addition of the substrate para-nitrophenylphosphate. Ab-
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H5N1 Cross-Protection from H1N1 Virussorbance at 405 nm was measured with an ELISA plate
reader, and endpoint titers were deﬁned as the serum
dilution at which the signal strength was twice that of
strain-matched control serum. The lower limit of IgG
detection was an endpoint titer of 20. Serum samples were
collected from 38 human volunteers. These samples were
assayed for NA-speciﬁc antibodies by a standard NA
inhibition method [13]. In brief, the neuraminidase activity
of each virus was standardized according to colorimetric
analysis of sialic acid release from fetuin substrate. Inhibition
titers were determined by the reduction of this activity after
virus incubation with serially diluted serum, when compared
with control reactions lacking serum. NA inhibition titers
were measured against A/New Caledonia/20/99, and reassor-
tant PR8 viruses containing the HA and NA of A/Hong Kong/
213/03, or A/Vietnam/1203/04. The HA of the latter two
viruses was manipulated to remove the polybasic amino acids
associated with high virulence. This allowed the handling of
these viruses at Biosafety Level 2 conditions.
Statistical Analysis
Statistical analysis of differences in mortality between
experimental and control treatment groups was performed
using a one-sided Fisher’s exact test. Statistical signiﬁcance
was designated for differences with p-values less than or equal
to 0.05. IgG titers measured by ELISA were log2 transformed,
and mean titers from the two treatment groups were
compared by Student’s t test. Samples lacking detectable
IgG (detection limit 20) were assigned a titer of 10 for
statistical calculations.
Results
The aim of the present study was to determine whether
immunity to huN1 provides sufﬁcient cross-reactive immun-
ity to avN1 to confer resistance to H5N1 inﬂuenza virus. To
this end, we vaccinated female BALB/cJ mice twice with a
plasmid encoding the NA of A/New Caledonia/20/99 (H1N1)
to induce NA-speciﬁc immunity. A/New Caledonia/20/99 is
the source of H1N1 antigen for currently available trivalent
inﬂuenza vaccines. Readily detectable antibody responses to
the homologous huN1 antigen were induced in nearly all
mice, as shown by ELISA (Figure 1A). In equivalent sera from
control mice, titers of antibodies to huN1 were essentially
undetectable, with a mean signiﬁcantly different from huN1-
immunized mice (p , 0.001). Using an equivalent ELISA, we
also tested samples for antibody reactivity with NA of A/
Vietnam/1203/04 (H5N1), which shares 80% amino acid
identity with NA of A/New Caledonia/20/99. Reactivity with
the heterologous avN1 was detected only in a small
proportion of serum samples of the huN1 DNA vaccinated
group (4/32) or the control mice (2/30) (Figure 1B), and the
difference in mean titers was statistically insigniﬁcant (p ¼
0.092). Sera from three mice in the huN1 DNA vaccinated
group had avN1-speciﬁc titers greater than 100, whereas no
sample from the control group possessed this level of
reactivity.
Mice vaccinated with huN1 DNA demonstrated robust
resistance to challenge with 10 MLD50 of PR8-huN1 (Figure
2A). Although all control mice lost a substantial amount of
weight and died from this challenge infection, all of the
vaccinated animals survived and largely recovered the weight
they lost early in the infection. Protection of vaccinated mice
against mortality from the homologous virus was highly
signiﬁcant (p , 0.001), which demonstrates the vaccine’s
potency. Challenge with 10 MLD50 of PR8-avN1 was also
100% lethal to control mice, whose disease course was similar
to that in mice infected with PR8-huN1 (Figure 2B). In
addition, challenge with PR8-avN1 at this dose caused greater
than 20% mean weight loss by day 7 in the mice vaccinated
Figure 1. NA-Specific Antibody Responses to Immunization
Serum was collected from BALB/cJ mice after two injections with plasmid
encoding the NA of human H1N1 influenza strain A/New Caledonia/20/
99 (huN1) or saline only. Antibody reactivities with huN1 and the NA of
H5N1 influenza strain A/Vietnam/1203/04 (avN1) were determined by
ELISA.
(A) Between the huN1 DNA and saline-only treatment groups there was a
statistically significant difference in mean IgG titers against huN1 (p ,
0.001).
(B) IgG titers detected against avN1 were not significantly different
between the treatment groups (p ¼ 0.092). The antibody titer against
each target was defined as the reciprocal of the highest serum dilution
that produced an ELISA signal twice as intense as the signal from
equivalently diluted naı ¨ve serum. The lower limit of detection was a titer
of 20.
doi:10.1371/journal.pmed.0040059.g001
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H5N1 Cross-Protection from H1N1 Viruswith huN1 DNA. However, a subset of vaccinated mice (4/11)
regained weight and survived, evidence that partial cross-
protection resulted from the immune response to huN1. The
difference in mortality between immunized and control
groups upon heterologous PR8-avN1 challenge approached
but did not reach statistical signiﬁcance (p ¼ 0.055). All mice
vaccinated with huN1 DNA were protected from mortality
upon a 100 MLD50 challenge dose of PR8-huN1 (p , 0.0001),
but cross-protection against heterologous PR8-avN1 at this
10-fold higher dose was weak (2/10 survival, p ¼ 0.26,
unpublished data).
The third viral challenge with H5N1 strain A/Vietnam/1203/
04 was highly lethal, as previously reported [11,14,15].
Infection with 10 MLD50 of A/Vietnam/1203/04 killed all
control mice (Figure 2C). Disease resulting from infection
with this H5N1 virus was more prolonged than that caused by
the PR8-based challenge viruses, and the infected naı ¨ve mice
showed a somewhat biphasic pattern of weight loss often
accompanied or followed by hind leg paralysis. In contrast,
mice vaccinated against huN1 typically had more moderate
weight loss and fewer of them showed neurological signs. Half
(5/10) of the vaccinated mice recovered from challenge with
the H5N1 inﬂuenza virus, which demonstrates statistically
signiﬁcant protection from mortality (p¼0.016). Against a 10-
fold higher challenge dose of H5N1 virus (100 MLD50)
vaccination with huN1 DNA failed to protect against mortal-
ity (unpublished data).
In an additional experiment we addressed the possibility
that the protection conferred by huN1 DNA against
heterologous challenge was a result of nonspeciﬁc stimulation
of the innate immune system, such as by CpG DNA motifs.
Along with mice receiving huN1 DNA recombinant plasmid, a
group of control mice received only the backbone plasmid
without a gene insert. Vaccination with the empty vector
failed to protect any animals against the lethal effects of A/
Vietnam/1203/04 (Figure 3). Owing to small treatment groups
in this experiment, the difference in mortality between mice
receiving huN1 DNA (4/8) versus saline (1/7) was not statisti-
cally signiﬁcant (p ¼ 0.18), but the difference between huN1
DNA and empty vector treatment (0/7) approached signiﬁ-
cance (p ¼ 0.051). Thus, we exclude nonspeciﬁc immune
stimulation by plasmid DNA as the mechanism for cross-
subtype protection.
We hypothesized that protection from H5N1 inﬂuenza by
huN1 immunization is mediated by the humoral immune
response. To test this hypothesis, we pooled sera from mice
injected twice with huN1 DNA (prechallenge), from mice
injected with saline only, or from mice that had recovered
from infection with H5N1 inﬂuenza virus, and we transferred
the sera intraperitoneally to naı ¨ve mice before challenging
them with 10 MLD50 of A/Vietnam/1203/04. Serum from
survivors of infection protected all recipient mice from
severe disease and death upon homologous challenge, where-
as mice that received serum from saline-injected animals
were highly susceptible to this challenge (1/13 survival)
(Figure 4). In comparison, serum from huN1 DNA–vaccinated
mice was partially protective: 46% (6/13) of recipient mice
survived challenge with A/Vietnam/1203/04, which represents
a statistically signiﬁcant difference from naı ¨ve serum (p ¼
0.037). This outcome closely mirrors that of the vaccinated
animals themselves. This set of results demonstrates that
huN1-induced immunity against H5N1 virus is mediated, at
least in large part, by a humoral response. The considerable
weight loss of the passively immunized mice that survived
challenge in this experiment might reﬂect a contribution by
cell-mediated immunity to cross-lineage protection. Alter-
natively, the discrepancy in recovery may be attributable to
the dilution of immune serum in passively immunized mice,
the lack of memory B cells in these mice, or stress resulting
from the serum transfer procedure.
We also tested serum samples from human volunteers for
reactivity with avN1. Analysis of these samples by NA
inhibition assay demonstrated reactivity with H1N1 inﬂuenza
virus A/New Caledonia/20/99 in 31 of 38 individuals tested
(Figure 5). NA inhibition titers in these samples ranged from
less than 20 to 320 or higher. We detected low inhibitory
activity (titers between 20 and 80) against the NA of A/Hong
Kong/213/03 in eight individuals and against the NA of A/
Figure 2. Challenge of huN1-Immunized Mice with Influenza Viruses Possessing Homologous or Heterologous NA Genes
Mice immunized twice with huN1 DNA or saline alone (control) were inoculated intranasally with PR8-huN1 (A), PR8-avN1 (B), or A/Vietnam/1203/04 (C).
Mean weight change and survival data are shown. Differences in survival between huN1 DNA-vaccinated and saline control groups were statistically
significant for PR8-huN1 challenge (p , 0.001) and A/Vietnam/1203/04 challenge (p ¼ 0.016), and approached but did not reach significance for PR8-
avN1 challenge (p ¼ 0.055). Error bars represent standard deviation values. Statistical comparisons are by Fisher’s exact test.
doi:10.1371/journal.pmed.0040059.g002
Figure 3. Sequence Dependence of huN1 DNA Vaccine Induced
Protection against Lethal H5N1 Infection
Mice vaccinated at week 0 and week 3 with huN1 DNA (n¼8), saline (n¼
7), or empty plasmid vector (n¼7) were challenged with 10 MLD50 of A/
Vietnam/1203/04 (H5N1) at week 6. Survival was monitored daily.
Although the difference in mortality between saline-injected and huN1
DNA–vaccinated groups did not reach statistical significance (p ¼ 0.18),
the difference in mortality between huN1 DNA vaccinated mice and
those given empty vector DNA approached significance (p ¼ 0.051).
Statistical comparison is by Fisher’s exact test.
doi:10.1371/journal.pmed.0040059.g003
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H5N1 Cross-Protection from H1N1 VirusVietnam/1203/03 in nine individuals. Of these H5N1–reactive
samples seven had reactivity to both H5N1 viruses. Although
this human donor sample size is small, the results establish
that some individuals have functionally signiﬁcant levels of
avN1-reactive antibodies.
Discussion
The common NA subtype between avian H5N1 and human
H1N1 inﬂuenza viruses raises the possibility that H1N1-
speciﬁc immunity could offer a degree of protection against
lethal H5N1 infection. Precedent for this possibility is found
in the onset of the 1968 Hong Kong inﬂuenza pandemic. With
respect to HA, the H3N2 virus responsible for this outbreak
was antigenically novel, but in terms of NA it could not be
distinguished from preceding H2N2 strains that descended
from the 1957 Asian inﬂuenza pandemic virus [16]. The H3N2
virus of 1968 was generally less lethal than previous pandemic
viruses, though the severity of disease varied across regions of
the globe [17,18]. It has been proposed that NA-speciﬁc
immunity against H2N2 virus moderated the virulence of
H3N2 virus in humans. Evidence for this has been provided
by epidemiological investigation [19], a human H2N2 vaccine
study [20], and mouse prime/challenge experiments [16].
Similarly, it was previously shown that immunity raised
against NA of a human H3N2 isolate by DNA vaccination
partially protects mice against lethal challenge with an
antigenically variant H3N2 virus [7].
Because H5N1 inﬂuenza virus has caused severe illness in
most known human infections despite the common occur-
rence of H1N1 infection in the human population, it could be
argued that immunity to huN1 is irrelevant in the face of
H5N1 infection. However, known human cases worldwide are
only a small sample set; a large number of mild cases may
have gone undetected. Unreported mild or asymptomatic
infection may be a frequent outcome of H5N1 exposure in
persons with strong H1N1 immunity. Serologic studies to
address this possibility would be valuable. The hypothesis that
huN1-induced immunity confers some degree of protection
against H5N1 virus implies that younger people, having a
shorter history of H1N1 exposure, may be disproportionately
susceptible to H5N1 infection. Consistent with this hypoth-
esis are ﬁndings from an analysis of 144 cases of human H5N1
infection since 2003, reported by the World Health Organ-
ization: 50% of infected patients were younger than 18 years
and 90% were 37 years or younger (Inﬂuenza Report, http://
www.inﬂuenzareport.com).
Our data demonstrate in a mouse model that the immune
response induced by the NA of human H1N1 inﬂuenza virus
constitutes a modest defense against challenge with lethal
doses of either PR8-avN1 or the H5N1 virus A/Vietnam/1203/
04. There was a disparity between the proportion of mice that
Figure 4. Cross-Protective Effects of huN1-Immune Serum against H5N1 Influenza
Mice were passively immunized with serum from mice that had recovered from H5N1 influenza virus infection (post-H5N1), were vaccinated twice with
huN1 DNA (N1 DNA), or were vaccinated twice with saline alone. Eighteen hours after passive immunization, recipient mice were challenged with 10
MLD50 of A/Vietnam/1203/04. Changes in mean weight (left graph) and survival (right graph) were monitored over 24 d. The difference in survival
between recipients of serum from huN1 DNA-vaccinated and saline control mice was statistically significant (p ¼ 0.037). Error bars represent standard
deviation values. Statistical comparison is by Fisher’s exact test.
doi:10.1371/journal.pmed.0040059.g004
Figure 5. Reactivity of Human Donor Sera with NA of H1N1 and H5N1
Influenza Viruses
Serum samples from human donors were analyzed by NA inhibition
assay for reactivity with the NA proteins of A/New Caledonia/20/99
(H1N1), A/Hong Kong/213/03 (H5N1), and A/Vietnam/1203/04 (H5N1).
doi:10.1371/journal.pmed.0040059.g005
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H5N1 Cross-Protection from H1N1 Viruspossessed detectable levels of cross-reactive IgG prior to
infection (12.5%) and the rate of cross-protection against
mortality (50% for A/Vietnam/1203/04). Because we later
observed that mice passively immunized with serum from
vaccinated animals were protected to a similar degree, it
appears that antibodies play a dominant role in cross-
protection. The IgG detection ELISA utilized here may lack
the sensitivity to differentiate antibody from other inhibitory
serum factors at low dilutions. Alternatively, cross-protective
antibodies could be IgM or IgA.
These results suggest that immunization against H1N1
inﬂuenza virus with trivalent vaccines containing NA protein
or via natural H1N1 infection can provide humans with some
degree of resistance to H5N1 inﬂuenza viruses. Because most
human inﬂuenza vaccines are inactivated, they are likely to
elicit a predominantly humoral immune response. In our
murine model, humoral immunity to huN1 is sufﬁcient to
mediate partial cross-lineage protection against H5N1
inﬂuenza. This ﬁnding underscores a possible beneﬁt of
seasonal inﬂuenza vaccination for a human population faced
with the threat of pandemic H5N1 inﬂuenza and, more
immediately, urges that emphasis be placed on increasing
human seasonal inﬂuenza vaccine usage in areas where H5N1
is endemic in avian species. However, taking advantage of the
potentially cross-protective property of NA may require that
the antigenic content of both surface glycoproteins, not only
HA, be standardized in licensed vaccines.
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Background. Every winter, millions of people catch influenza—a viral
infection of the airways. Most recover quickly but influenza can kill
infants, elderly people, and chronically ill individuals. To minimize these
deaths, the World Health Organization recommends that vulnerable
people be vaccinated against influenza every autumn. Annual vacci-
nation is necessary because flu viruses continually make small changes to
the viral proteins (antigens) that the immune system recognizes. Each
year’s vaccine contains disabled versions of the circulating strains of
influenza A type H1N1 and H3N2 viruses, and of influenza B virus. The H
and N refer to the major influenza A antigens (hemagglutinin and
neuraminidase), and the numbers refer to the type of each antigen;
different H1N1 and H3N2 virus strains contain small variations in their
respective hemagglutinin and neuraminidase type. Vaccines provide
protection against seasonal influenza outbreaks, but sometimes flu
viruses emerge that contain major antigenic changes, such as a different
hemagglutinin type. These viruses can start pandemics (global out-
breaks) because populations have little immunity to them. Many
scientists believe that avian (bird) H5N1 influenza virus (which has
caused about 250 confirmed cases of human flu and 150 deaths) could
trigger the next human pandemic.
Why Was This Study Done? Avian influenza H5N1 virus has not started
a human pandemic yet because it cannot move easily between people. If
it acquires this property, it could kill millions before an effective vaccine
could be developed, so researchers are looking for other ways to provide
protection against avian H5N1. One possibility is that an immune
response to the human type 1 neuraminidase (huN1) in circulating H1N1
influenza virus strains and vaccines could provide some protection
against avian H5N1 influenza virus, which contains the closely related
avian type 1 neuraminidase (avN1). In this study, the researchers have
investigated this possibility in mice and in a small human study.
What Did the Researchers Do and Find? The researchers immunized
mice with DNA encoding the huN1 present in a circulating H1N1 virus.
They then examined the immune response of the mice to this huN1 and
to avN1 from an avian H5N1 virus isolated from a human patient (A/
Vietnam/1203/04). Most of the mice made antibodies (proteins that
recognize antigens) against huN1; a few also made detectable levels of
antibodies against avN1. All the vaccinated mice survived infection with
a man-made flu virus containing huN1, and half also survived infection
with low doses of a man-made virus containing avN1 or A/Vietnam/
1203/04. To test whether the antibodies made by the vaccinated mice
were responsible for this partial protection, the researchers collected
serum (the liquid part of blood that contains the antibodies) from them
and injected it into unvaccinated mice. Again, about half of the mice
survived infection with the H5N1 virus, which indicates that the huN1-
induced immunity against H5N1 is largely mediated by antibodies.
Finally, the researchers tested serum samples from 38 human volunteers
for their ability to inhibit neuraminidase from an H1N1 virus and two
H5N1 viruses (antibodies to neuraminidase reduce viral replication and
disease severity by inhibiting neuraminidase activity). Most of the sera
inhibited the enzyme from the H1N1 virus; and seven also inhibited the
enzyme from both H5N1 viruses.
What Do These Findings Mean? These findings indicate that a vaccine
containing huN1 induces the production of antibodies in mice that partly
protect them against H5N1 infection. In addition, the human study
suggests that some people may have some degree of resistance to H5N1
influenza because of exposure to H1N1 viruses or routine influenza
vaccination. These results, while intriguing, don’t show that there is
actual protection, but it seems well worth doing additional work to
address this question. The researchers also suggest that many more
people might have been infected already with H5N1 but their strong
H1N1 immunity meant they had only mild symptoms, and this
hypothesis also deserves further investigation. Overall, these findings
raise the possibility that seasonal influenza vaccination may provide
some protection against pandemic H5N1. It is worth discussing whether,
even while further studies are underway, seasonal vaccination should be
increased, especially in areas where H5N1 is present in birds.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040059.
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